Isocitrate dehydrogenase inhibitors in acute myeloid leukemia
Abstract Isocitrate dehydrogenase (IDH) is a key enzyme involved in the conversion of isocitrate to α-ketoglutarate (α-KG) in the tricarboxylic acid (TCA) cycle. IDH mutation produces a neomorphic enzyme, which can lead to the abnormal accumulation of R-2-HG and promotes leukemogenesis. IDH mutation...
Saved in:
Main Authors: | Xiaoyan Liu (Author), Yuping Gong (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2019-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer
by: Yang Liu, et al.
Published: (2023) -
Isocitrate Dehydrogenase Inhibitors in Glioma: From Bench to Bedside
by: Merve Hazal Ser, et al.
Published: (2024) -
Cytosolic Isocitrate Dehydrogenase from Arabidopsis thaliana Is Regulated by Glutathionylation
by: Adnan Khan Niazi, et al.
Published: (2019) -
Discovery of novel enasidenib analogues targeting inhibition of mutant isocitrate dehydrogenase 2 as antileukaemic agents
by: Ahmed F. Khalil, et al.
Published: (2023) -
Functions of RNA N6-methyladenosine modification in acute myeloid leukemia
by: Xue Zheng, et al.
Published: (2021)